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Which combined OC to prescribe 
with CV safety in mind? 
With various formulations available, which combined 
OC should you recommend to minimize not only the risk 
of PE, but also the risk of stroke and MI?
PRACTICE CHANGER
When prescribing combined oral contracep-
tives, choose one containing levonorgestrel 
and low-dose estrogen (20 mcg) to minimize 
the risks of pulmonary embolism, ischemic 
stroke, and myocardial infarction.
STRENGTH OF RECOMMENDATION 
B: Based on a good quality, patient-oriented 
cohort study.
Weill A, Dalichampt M, Raguideau F, et al. Low dose oestrogen com-
bined oral contraception and risk of pulmonary embolism, stroke, and 
myocardial infarction in five million French women: cohort study. 
BMJ. 2016;353:i2002.1
ILLUSTRATIVE CASE 
A 28-year-old woman presents to your office 
for a routine health maintenance examination. 
She is currently using an oral contraceptive 
containing desogestrel and ethinyl estradiol 
for contraception and is inquiring about a 
refill for the coming year. What would you 
recommend? 
When choosing a combined oral contraceptive (COC) for a patient, physicians often have “go-to” fa-
vorites—tried and true agents that are easy to 
prescribe on a busy clinic day. However, some 
of these may be placing patients at increased 
risk for venous thromboembolic events. 
In general, when compared with nonus-
ers, women who use COCs have a 2- to 4-fold 
increase in risk of venous thromboembolism 
(VTE) and an increased risk of myocardial in-
farction (MI) and stroke.2,3 More specifically, 
higher doses of estrogen combined with the 
progesterones gestodene, desogestrel, and 
levonorgestrel, are associated with a higher 
risk of VTE.2-6
In 2012, the European Medicines Agency 
warned that COCs containing drospirenone 
were associated with a higher risk of VTE than 
other preparations, despite similar estrogen 
content.7 The US Food and Drug Administra-
tion (FDA) produced a similar statement that 
same year, recommending that physicians 
carefully consider the risks and benefits be-
fore prescribing contraceptives containing 
drospirenone.8 
The risks of ischemic stroke and MI have 
not been clearly established for varying doses 
of estrogen and different progesterones. This 
large observational study fills that informa-
tional gap by providing risk estimates for the 
various COC options.
STUDY SUMMARY
One combined oral contraceptive 
comes out ahead 
The authors used an observational cohort 
model to determine the effects of different 
doses of estrogen combined with different 
progesterones in COCs on the risks of pulmo-
nary embolism (PE), ischemic stroke, and MI.1 
Data were collected from the French national 
health insurance database and the French 
national hospital discharge database.9,10 The 
study included just under 5 million women 
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15 to 49 years of age, living in France, with at 
least one prescription filled for COCs between 
July 2010 and September 2012. 
The investigators calculated the absolute 
and relative risks of first PE, ischemic stroke, 
and MI in women using COC formulations 
containing either low-dose estrogen (20 mcg) 
or high-dose estrogen (30-40 mcg) combined 
with one of 5 progesterones (norethisterone, 
norgestrel, levonorgestrel, desogestrel, ges-
todene). The relative risk (RR) was adjusted 
for confounding factors, including age, com-
plimentary universal health insurance, socio-
economic status, hypertension, diabetes, and 
consultation with a gynecologist in the previ-
ous year. 
❚ The absolute risk per 100,000 woman-
years for all COC use was 33 for PE, 19 for 
ischemic stroke, and 7 for MI with a composite 
risk of 60. The RRs for low-dose estrogen vs 
high-dose estrogen were 0.75 (95% confidence 
interval [CI], 0.67-0.85) for PE, 0.82 (95% CI, 
0.7-0.96) for ischemic stroke, and 0.56 (95% CI, 
0.39-0.79) for MI. The absolute risk reduction 
(ARR) with low-dose estrogen vs high-dose es-
trogen was 14/100,000 person-years of use; the 
number needed to harm (NNH) was 7143. 
Compared with levonorgestrel, desoges-
trel and gestodene were associated with higher 
RRs of PE but not arterial events (2.16; 95% 
CI, 1.93-2.41 for desogestrel and 1.63; 95% 
CI, 1.34-1.97 for gestodene). The ARR with 
levonorgestrel use as opposed to desogestrel 
for PE was 19/100,000 person-years of use 
(NNH=5263); the ARR with levonorgestrel 
use as opposed to gestodene was 12/100,000 
person-years of use (NNH=8333). The authors 
concluded that for the same progesterone, 
using a lower dose of estrogen decreases risk 
of PE, ischemic stroke, and MI, and that oral 
contraceptives containing levonorgestrel and 
low-dose estrogen resulted in the lowest over-
all risks of PE and arterial thromboembolism.
WHAT’S NEW?
Low-dose estrogen and levonorgestrel 
confer lowest risk of 3 CV conditions
Prior studies have shown that COCs increase 
the risk of PE and may also increase the risks 
of ischemic stroke and MI.3,11 Studies have 
also suggested that a higher dose of estrogen 
in COCs is associated with an increased risk 
of VTE.11,12 This study shows that 20 mcg of 
estrogen combined with levonorgestrel is as-
sociated with the lowest risks of PE, MI, and 
ischemic stroke.
CAVEATS
A cohort study, no contraceptive start 
date, and incomplete tobacco use data
This is an observational cohort study, so it is 
subject to confounding factors and biases. It 
does, however, include a very large popula-
tion, which improves validity. The study did 
not account for COC start date, which may be 
confounding because the risk of VTE is high-
est in the first 3 months to one year of COC 
use.12 Data on tobacco use, a significant inde-
pendent risk factor for arterial but not VTE, 
was incomplete, but in other studies has only 
marginally affected outcomes.3,13
CHALLENGES TO IMPLEMENTATION
Low-dose estrogen is associated 
with increased vaginal spotting
One potential challenge to implementing this 
practice changer may be the increased rate 
of vaginal spotting associated with low-dose 
estrogen. COCs containing 20 mcg of estro-
gen are associated with spotting in approxi-
mately two-thirds of menstrual cycles over 
the course of a year.14 That said, women may 
prefer to endure the spotting in light of the 
improved safety profile of a lower-dose estro-
gen pill.                     JFP
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